肿瘤血管靶向治疗的研究进展  

Research development of solid tumor vascular-targeted therapy

作　　者：吴学元[1] 马巍[2] 任国文[1] 王振汉[1] 张党风[2] 

机构地区：[1]西安高新医院骨科,陕西西安710065 [2]西安交通大学第一附属医院骨科,陕西西安710061

出　　处：《现代肿瘤医学》2009年第1期121-125,共5页Journal of Modern Oncology

摘　　要：肿瘤血管在实体瘤的发生发展中具有重要的作用,靶向肿瘤血管的抑制在抗肿瘤治疗已得到广泛的认同,并生产出大批抗血管制剂,有的已应用于临床治疗。这些新研发的抗血管制剂与传统的针对实体瘤的细胞毒性药物作用机理截然不同。根据作用机理及对血管抑制的阶段不同,肿瘤血管靶向治疗分为抗血管新生制剂和肿瘤血管阻断制剂。抗血管新生制剂旨在抑制肿瘤新生血管新生过程,而肿瘤血管阻断制剂则通过快速而有选择性地损坏或阻塞已构建完成的肿瘤血管,使肿瘤血供受阻引起肿瘤坏死。两者区别主要在作用靶点、肿瘤类型及治疗时机不同。本文对近年来抗血管新生制剂和血管阻断剂的研究进展进行综述。The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number of which are currently in clinical development. These novel agents are quite distinct from the cytotoxic drugs conventionally used in the treatment of sol- id tumors. Based on the differece of the treatment machanisms and stages, two distinct groups of vascular - targeted therapies have evolved ： antiangiogenic agents and vascular - disrupting agents. Antiangiogenic agents interfere with new vessel formation,while vascular- disrupting agents targetthe established tumor blood vessels, resulting in tumor ischemia and necrosis. These differ in their targets, the type or extent of disease that is likely to be susceptible, and the treatment scheduling. We present a review on recent research related to the antiangiogenic agents and vasculardisrupting agents.

关 键 词：肿瘤血管靶向治疗 抗血管新生制剂 肿瘤血管阻断制剂 

分 类 号：R730.5[医药卫生—肿瘤]